SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Indivior PLC announced that it was added to the S&P SmallCap 600 index on December 22, 2025, following earlier inclusions in the S&P 1000 and the S&P Pharmaceuticals Select Industry Index and ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

On January 8, 2026, Indivior issued full-year 2026 financial guidance, projecting total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected at $905 million to ...

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...

Shares of Indivior (NASDAQ:INDV) dropped on Thursday after the dual-listed U.S. drugmaker lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related ...

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics.

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...

Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine ...